NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 36.24 P/S
- 17.36 P/B
- -0.31 EPS
- -2,078.99% Cash ROIC
- 1.62 Cash Ratio
- 0 / 0% Dividend
- 328,733.00 Avg. Vol.
- 49.63M Shares
- 39.72M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Dakota Financial News - 8 hours ago
Seeking Alpha - Apr 21, 2015
Benzinga - Apr 16, 2015
wsnewspublishers - Apr 22, 2015
Business Wire (press release) - Apr 14, 2015
StreetInsider.com - Apr 14, 2015
Seeking Alpha (registration) - Mar 27, 2015
Seeking Alpha - Jan 7, 2015
Business Wire (press release) - Mar 16, 2015
Business Wire (press release) - Mar 9, 2015